Sinoway Industrial Co., Ltd.

Imatinib Mesylate 220127-57-1 Imatinib Mesylate 220127-57-1

Imatinib Mesylate 220127-57-1
Related Products
  • Mupirocin 12650-69-0

    Details of MupirocinOther Names: mupirocinMF: C26H44O9Place of Origin: Fujian, China (Mainland)Type: Auxiliaries and Other Medicinal Chemicals, Immune Function AgentsGrade Standard: Medicine GradeBran...

  • Atracurium Besylate 64228-81-5

    Basic information of Atracurium besylate:NameAtracurium besylateAliasCAS NO.64228-81-5 Molecular FormulaC65H82N2O18S2Molecular Weight1243.48Quality StandardCurrent USPPackage Size2kg or 3kg/tin/carton...

  • Ceftiofur Sodium 104010-37-9

    Basic information of Ceftiofur sodium:NameCeftiofur sodiumCAS :104010-37-9Molecular FormulaC19H16N5NaO7S3Molecular Weight545.54Quality StandardPackage SizeFor small quantity:Double plastic bag inside ...

Basic information of Imatinib Mesylate

Name

Imatinib Mesylate

Alias

GLIVEC;GLEEVEC;IMATINIB METHANESULFONATE; CGP-57148B;
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-phenyl]-benzamide Mesylate;

CAS NO.

220127-57-1

Molecular Formula

C30H35N7O4S

Molecular Weight

589.71

Quality Standard

In-house Standard

Package Size

Aluminium bag; 50g/bag; 100g/bag

Brief Introduction

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl,
the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of
dermatological diseases. Imatinib has been reported to be an effective treatment for
FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Storage condition

Preserve in tight, light-resistant containers, and store at 15℃—30℃.

Use of Imatinib Mesylate

  • A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
  • echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
  • Anticancer

COA of Imatinib Mesylate

TEST ITEM

SPECIFICATION

RESULTS

Appearance

White or slightly yellow crystalline powder,
homogeneous and with fine grain size.
No foreign particles are observed.

Slightly yellow crystalline Powder

Solubility

Soluble in water and in acids solutions, slightly soluble
in methanol insoluble in acetone, acetonitrile and
dilute hydroxyl alkaline solution

Confirm

Identification

Complies

Confirm

Water

≤1.0%

0.8%

Heavy metals

≤20ppm

10ppm

Melting range

212 – 220℃

214-216℃

Residue on ignition

≤0.1%

0.08%

Particle size

90% < 100 μm

50% < 50 μm

Confirm

Bulk density

NLT 0.4g/ml

0.6g/ml

Chromatographic

purity

Individual impurities: ≤0.2%

Total impurities: ≤0.5%

0.16%

0.32%

Assay

98.5%-102.0% of Imatinib mesylate,

calculated on anhydrous basis.

99.70%



Residual solvents

Ethyl acetate: ≤5000ppm

Confirm

Acetone: ≤5000ppm

Confirm

N,N-Dimethylformamide: ≤880ppm

Confirm

Methanol: ≤3000ppm

Confirm

Dichloromethane: ≤300ppm

Confirm



MORE_DETAIL Imatinib Mesylate 220127-57-1

Basic information of Imatinib Mesylate

Name

Imatinib Mesylate

Alias

GLIVEC;GLEEVEC;IMATINIB METHANESULFONATE; CGP-57148B;
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-phenyl]-benzamide Mesylate;

CAS NO.

220127-57-1

Molecular Formula

C30H35N7O4S

Molecular Weight

589.71

Quality Standard

In-house Standard

Package Size

Aluminium bag; 50g/bag; 100g/bag

Brief Introduction

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl,
the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of
dermatological diseases. Imatinib has been reported to be an effective treatment for
FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Storage condition

Preserve in tight, light-resistant containers, and store at 15℃—30℃.

Use of Imatinib Mesylate

  • A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
  • echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
  • Anticancer

COA of Imatinib Mesylate

TEST ITEM

SPECIFICATION

RESULTS

Appearance

White or slightly yellow crystalline powder,
homogeneous and with fine grain size.
No foreign particles are observed.

Slightly yellow crystalline Powder

Solubility

Soluble in water and in acids solutions, slightly soluble
in methanol insoluble in acetone, acetonitrile and
dilute hydroxyl alkaline solution

Confirm

Identification

Complies

Confirm

Water

≤1.0%

0.8%

Heavy metals

≤20ppm

10ppm

Melting range

212 – 220℃

214-216℃

Residue on ignition

≤0.1%

0.08%

Particle size

90% < 100 μm

50% < 50 μm

Confirm

Bulk density

NLT 0.4g/ml

0.6g/ml

Chromatographic

purity

Individual impurities: ≤0.2%

Total impurities: ≤0.5%

0.16%

0.32%

Assay

98.5%-102.0% of Imatinib mesylate,

calculated on anhydrous basis.

99.70%



Residual solvents

Ethyl acetate: ≤5000ppm

Confirm

Acetone: ≤5000ppm

Confirm

N,N-Dimethylformamide: ≤880ppm

Confirm

Methanol: ≤3000ppm

Confirm

Dichloromethane: ≤300ppm

Confirm


Related Articles
Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//